10-Q: DENTSPLY SIRONA Inc. Q1 2026 Earnings Decline Amid Restructuring

DENTSPLY SIRONA Inc. reported a net loss of $10 million for the first quarter of 2026, a significant shift from the prior year's profit, driven by increased restructuring costs and lower gross profit margins.

Summary

• DENTSPLY SIRONA Inc. reported a net loss of $10 million for the first quarter ended March 31, 2026, compared to a net income of $20 million in the same period of 2025.
• Net sales were $880 million, a slight increase of 0.1% as reported, but a decrease of 6.7% on a constant currency basis.
• Gross profit decreased by 8.3% to $427 million, with gross profit margin declining to 48.5% from 53.0% in the prior year.
• Selling, general, and administrative (SG&A) expenses decreased by 2.0% to $351 million.
• Research and development (R&D) expenses increased by 22.0% to $44 million.
• Restructuring and other costs significantly increased to $67 million from $9 million in the prior year, primarily due to a new restructuring plan approved in February 2026.
• The company expects the 2026 Plan to result in approximately $120 million in annualized cost savings, with a majority of charges expensed and paid in 2026 and 2027.
• Cash provided by operating activities was $40 million, an increase from $7 million in the prior year.
• Capital expenditures were $53 million, up from $19 million in the prior year.
• The company ended the quarter with $190 million in cash and cash equivalents.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing as negative due to the net loss, declining gross margins, and significant increase in restructuring costs, despite some operational improvements and positive cash flow from operations.

Positives

• Net sales showed a slight increase of 0.1% as reported, reaching $880 million.
• Cash provided by operating activities significantly increased to $40 million from $7 million in the prior year.
• Research and development expenses increased by 22.0% to $44 million, indicating investment in future growth and innovation, particularly in DS Core.
• The company expects the new restructuring plan (2026 Plan) to yield approximately $120 million in annualized cost savings.
• The company has $1.2 billion of authorization remaining under its share repurchase program.
• The company ended the quarter with $190 million in cash and cash equivalents, and $684 million of borrowings available under lines of credit.

Negatives

• The company reported a net loss of $10 million for the quarter, a reversal from a $20 million net income in the prior year.
• Net sales decreased by 6.7% on a constant currency basis, indicating underlying operational challenges.
• Gross profit margin declined significantly to 48.5% from 53.0% in the prior year.
• Restructuring and other costs surged to $67 million from $9 million, impacting profitability.
• Orthodontic and Implant Solutions segment adjusted operating income decreased by 78.4% to $8 million.
• Connected Technology Solutions segment reported an adjusted operating loss of $6 million, a reversal from a $7 million profit.
• The company eliminated the declaration of quarterly dividends on its common stock starting in the quarter ending March 31, 2026.

Risks

• The company is subject to ongoing securities litigation related to alleged false and misleading statements regarding revenue recognition and distributor rebate programs.
• Stockholder derivative suits have been filed alleging breaches of fiduciary duties and insider trading.
• The company is involved in a legal proceeding in Italy regarding an alleged failure to pay a portion of a purchase price for an acquisition, though an arbitral tribunal rejected the claims.
• The IRS is examining the company's tax returns for 2015 and 2016, with a proposed adjustment that could result in additional federal income taxes.
• The General Public Prosecutors Office Frankfurt am Main is investigating intercompany loans implemented in 2016 and 2017.
• The company faces risks related to global economic conditions, including inflation, supply chain constraints, and geopolitical tensions.
• Recent tariff policies and changes in trade policy could impact the company's supply chain, costs, and sales.
• The company's business is subject to quarterly fluctuations due to seasonality.

Future Outlook

The company expects to incur non-recurring charges in the approximate range of $60 million to $65 million related to the 2026 Plan, the majority of which will be expensed and paid in cash in 2026 and 2027. The 2026 Plan is anticipated to result in approximately $120 million in annualized cost savings. The company intends to reinvest a portion of these savings in targeted growth initiatives. Capital expenditures are estimated to be in the range of $125 million to $150 million for the full year 2026. The company expects to continue to finance operating cash requirements, capital expenditures, and debt service from current cash, cash flows from operations, and amounts available under its existing borrowing facilities.

Management Comments

• The Company seeks to improve operational performance and drive stockholder value creation through the 2026 Plan.
• The Company intends to reinvest a portion of the anticipated savings from the 2026 Plan in targeted return-to-growth initiatives, including investments in accelerated innovation, clinical education, and sales team education focused on connected dentistry.

Industry Context

StockSavvy.ai notes that DENTSPLY SIRONA's Q1 2026 results reflect broader industry challenges including macroeconomic headwinds, supply chain issues, and the impact of geopolitical events. The company's strategic focus on digital workflows and innovation, particularly through its DS Core platform, aligns with industry trends towards digitalization in dentistry. However, the significant restructuring costs and decline in gross margins highlight the immediate pressures faced by dental product manufacturers.

Comparison to Industry Standards

• DENTSPLY SIRONA's gross profit margin of 48.5% for Q1 2026 is below the typical range for established dental equipment and consumables manufacturers, which often see margins in the mid-50s to low-60s, depending on product mix and scale.
• The increase in R&D spending to 5.0% of net sales is in line with or slightly above the industry average for dental technology companies investing in innovation.
• The company's net loss in Q1 2026 contrasts with many competitors who have maintained profitability, though the significant restructuring charges are a specific factor impacting DENTSPLY SIRONA's reported earnings.
• Competitors like Envista Holdings (NVST) and Henry Schein (HSIC) may offer comparative benchmarks for operational efficiency and margin management in the current economic climate.

Legal Proceedings

• The company is a defendant in consolidated securities litigation alleging violations of U.S. securities laws related to revenue recognition and distributor rebate programs.
• Stockholder derivative suits have been filed alleging breaches of fiduciary duties, corporate waste, and insider trading.
• A claim has been filed in Italy seeking payment of a portion of a purchase price for an acquisition, though an arbitral tribunal rejected the claims.
• The IRS is examining the company's U.S. federal income tax returns for 2015 and 2016, with a proposed adjustment related to an internal reorganization.
• The General Public Prosecutors Office Frankfurt am Main is investigating intercompany loans implemented in 2016 and 2017.

Stakeholder Impact

• Shareholders: The net loss, elimination of dividends, and ongoing litigation may negatively impact shareholder value and confidence.
• Employees: Restructuring actions may lead to workforce reductions, impacting employee morale and job security.
• Customers: Increased costs due to tariffs or supply chain issues could potentially lead to higher product prices.
• Creditors: The company's financial performance and restructuring efforts will be monitored by creditors, though covenants are currently met.

Next Steps

• Implement the 2026 Plan to improve operational performance and achieve $120 million in annualized cost savings.
• Reinvest a portion of savings into targeted growth initiatives such as accelerated innovation, clinical education, and sales team education.
• Continue to monitor and mitigate the impacts of global economic conditions, trade policies, and geopolitical conflicts.
• Manage inventory levels, particularly for EDS products in EMEA and CAD/CAM and imaging products in CTS.
• Continue with the multi-year ERP system implementation project.

Key Dates

Recommendation

While the Q1 2026 results show a net loss and declining margins, the company is undertaking significant restructuring to improve future performance and expects substantial cost savings. The increase in operating cash flow and continued investment in R&D are positive signs. However, the ongoing litigation, increased restructuring costs, and negative constant currency sales growth warrant caution. A 'hold' recommendation reflects a balanced view of the near-term challenges and the potential for future recovery driven by the restructuring initiatives.

Keywords

DENTSPLY SIRONA, 10-Q, Quarterly Report, Financial Results, Restructuring, Net Loss, Net Sales, Gross Profit, Dental Products, Medical Devices, SEC Filing, XRAY